Biotechnology cancer Clinical Trials Prodrug

Moffitt Researchers Discover New Targets for Approved Cancer Drug

New study shows ALK inhibitor ceritinib may have the ability to be used for more than ALK-rearranged non-small cell lung cancer Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test […]

Biotechnology Immunotherapies Pharmaceuticals

Drug targeting technique could aid therapies for immune diseases

A new technique that targets drugs to specific cells could lead to improved therapies for diseases caused by an overactive immune response. The approach could help people affected by conditions such as arthritis and inflammatory bowel diseases, where the body’s own immune system mistakenly attacks healthy tissues. Researchers focused on a group of immune cells […]

Biotechnology cancer Prodrug

Inhibitor drug improves overall survival in older radioiodine resistant thyroid cancer

The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The study, published today in the Journal of Clinical Oncology, is the first to show lenvatinib […]

cancer Prodrug

Drug Developed at University of Minnesota Increases Survival in Dogs with Cancer

A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published today in the journal Molecular Cancer Therapeutics. “This is likely the most significant advance in the treatment of canine HSA in the last three […]

Alzheimers and Dementia Biotechnology Prescriptions

Eli Lilly, Biogen, and Neurotrope Fight to Find Viable Treatment for Alzheimer’s Disease

Repeated attempts to treat or even slow the relentless progression of Alzheimer’s disease by targeting just one red flag in patient’s brains have continued to lead to disappointing outcomes. Last Sunday “Sixty Minutes” episode aired on Columbian extended families that inherited a genetic defect that causes early onset Alzheimer’s, by the time they reach 45 […]